Xian Zheng

Dr. Xian Zheng

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
BYBao-Fei Yan
Bao-Fei Yan
XCXi Chen
Xi Chen
YCYa-Fang Chen
Ya-Fang Chen
SLSheng-Jin Liu
Sheng-Jin Liu
CXChen-Xin Xu
Chen-Xin Xu
JLJia Liu
Jia Liu

9 December 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
BYBao-Fei Yan
Bao-Fei Yan
YWYun Wang
Yun Wang
WWWen-Bo Wang
Wen-Bo Wang
XDXiao-Jun Ding
Xiao-Jun Ding
BWBin Wei
Bin Wei
XZXian Zheng
Xian Zheng

21 August 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
BYBao-Fei Yan
Bao-Fei Yan
LPLan-Fen Pan
Lan-Fen Pan
YQYi-Fang Quan
Yi-Fang Quan
QSQian Sha
Qian Sha
JZJing-Zheng Zhang
Jing-Zheng Zhang
XZXian Zheng
Xian Zheng
Hepatocellular carcinoma (HCC) is a malignancy with a high incidence and fatality rate worldwide. Hepatitis B virus (HBV) infection is one of the most important risk factors for its occurrence and development. Early detection of HBV-associated HCC (HBV-HCC) can improve clinical decision-making and patient outcomes. Biomarkers are extremely helpful, not only for early diagnosis, but also for the development of therapeutics. MicroRNAs (miRNAs), a subset of non-coding RNAs approximately 22 nucleotides in length, have increasingly attracted scientists’ attention due to their potential utility as biomarkers for cancer detection and therapy. HBV profoundly impacts the expression of miRNAs potentially involved in the development of hepatocarcinogenesis. In this review, we summarize the current progress on the role of miRNAs in the diagnosis and treatment of HBV-HCC. From a molecular standpoint, we discuss the mechanism by which HBV regulates miRNAs and investigate the exact effect of miRNAs on the promotion of HCC. In the near future, miRNA-based diagnostic, prognostic, and therapeutic applications will make their way into the clinical routine.

8 September 2022 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
BZBonan Zhao
Bonan Zhao
XLXiang Li
Xiang Li
YKYing Kong
Ying Kong
WWWenbo Wang
Wenbo Wang
TWTingting Wen
Tingting Wen
XZXian Zheng
Xian Zheng
Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems.

19 February 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XZXiao-Ren Zhu
Xiao-Ren Zhu
JZJia-Qi Zhu
Jia-Qi Zhu
QGQian-Hui Gu
Qian-Hui Gu
NLNa Liu
Na Liu
JLJing-Jing Lu
Jing-Jing Lu
YJYong Ji
Yong Ji
The tumor microenvironment (TME) is pivotal in non-small cell lung cancer (NSCLC) progression, influencing drug resistance and immune cell behavior through complex ligand-receptor (LR) interactions. This study developed an epithelial LR-related prognostic risk score (LRrisk) to identify biomarkers and targets in NSCLC. We identified twenty epithelial LRs with significant prognostic implications and delineated three molecular NSCLC subtypes with distinct outcomes, pathological characteristics, biological pathways, and immune profiles. The LRrisk model was constructed using twelve differentially expressed ligand-receptor interaction-related genes (LRGs), with a focus on POPDC3 (popeye domain-containing protein 3), which was overexpressed in NSCLC cells. Functional assays revealed that POPDC3 knockdown reduced cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), while its overexpression promoted cancerous activities. In vivo, POPDC3 silencing hindered, and its overexpression accelerated the growth of NSCLC xenografts in nude mice. Additionally, high expression levels of POPDC3 in NSCLC tissues were associated with enhanced CD4+ T cell infiltration and increased PD-1 expression within the TME. Moreover, ectopic POPDC3 overexpression in C57BL/6 J mouse Lewis lung carcinoma (LLC) xenografts enhanced CD4+ T cell infiltration and PD-1 expression in the TME. This research establishes a robust epithelial LR-related signature, highlighting POPDC3 as a critical facilitator of NSCLC progression and a potential therapeutic target.